-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Antiprogrammed cell death-1 antibody monotherapy is part of standard therapy for cutaneous melanoma, but is less effective against mucosal melanoma
This is a multicenter, open-label, single-group, phase 2 trial using Simon's two-stage design that enrolled patients aged 18 to 75 years with
A total of 43 patients were recruited, including 20 (46.
Overall, 90.
In summary, the combination regimen of atizumab and bevacizumab has shown predictable efficacy and controllable safety
Original Source:
Lili Mao, Meiyu Fang, Yu Chen, et al.